The Pulse Newsletter Expert heart health, in plain English. Fortnightly, from our clinicians. Subscribe →

Beta-Blockers: Uses, Side Effects, and Precautions

Beta-blockers

Beta-blockers calm the heart by blocking adrenaline, and they treat far more than blood pressure. Here is what yours is doing, the side effects worth knowing about including vivid dreams, and why you must never stop one suddenly.

Statin Muscle Aches: When It’s the Drug and When It Isn’t

Statin Muscle Aches
Key Points

  • Muscle symptoms on statins are real for a significant number of people, and dismissing them is one of the fastest ways to lose a patient’s trust and their willingness to take any cholesterol treatment at all.
  • The first question is not which statin to try next. It is whether the statin was clearly indicated in the first place, and that means looking at overall cardiovascular risk rather than a single cholesterol number.
  • Rechallenge studies show that a large proportion of people who stopped a statin for muscle aches can tolerate one when it is reintroduced carefully, often at a lower dose or a different agent.
  • True statin-related muscle injury with markedly raised creatine kinase is uncommon. Serious rhabdomyolysis is rare.
  • Lower doses, alternative statins, and non-daily dosing schedules are all used in practice to keep people on treatment, and much of the benefit comes from plaque stabilisation and reduced arterial inflammation rather than the LDL number alone.
  • Stopping a statin without a plan is the outcome worth avoiding, because the risk it was managing does not go away.

Aches in the thighs. Heaviness climbing stairs that was not there last year. Calves that feel like they have been through a session at the gym on a day with no gym. When someone describes this to me a few weeks after starting a statin, I do not think they are imagining it, and I do not open with the trial data.

I open by asking why they are on it.

That question surprises people. They assume the conversation will be about swapping to a different tablet. Often the more useful conversation is one step earlier, and it changes what we do next.

Why the Indication Matters More Than the Side Effect

A large number of statin prescriptions are written quickly. A cholesterol result comes back above a threshold, a script is generated, and the patient leaves with a tablet and very little sense of what it is protecting them from. Nobody set out to do it badly. Consultations are short and a number on a page is an easy thing to act on.

The trouble is that a cholesterol level on its own is a poor guide to whether an individual needs treatment. What matters is absolute cardiovascular risk, which is built from age, blood pressure, smoking history, diabetes, family history, kidney function, and whether there is any established arterial disease. Newer markers add further detail, including inflammation in the artery wall and, for some, ancestry, since cardiovascular risk runs higher in South Asian and East Asian populations. Two people with identical LDL readings can have completely different reasons to take a statin, or not to.

So when someone comes to me with muscle symptoms, the first thing I want to establish is which category they are in.

Established cardiovascular disease

If someone has had a heart attack, a stent, bypass surgery, a stroke, or has known atherosclerosis on imaging, the case for lipid-lowering therapy is strong and the effort to find a tolerable option is worth making. Here the goal is to stay on treatment in some form, and abandoning it entirely is the worst of the available outcomes.

Primary prevention with genuinely elevated risk

Someone with no established disease but a high calculated risk, a strong family history, or an elevated lipoprotein(a) also has a solid reason to persist. A coronary calcium score can add useful information when the decision is genuinely uncertain, because it reflects calcified plaque already present in that person’s own arteries rather than an estimated percentage. It has real limitations, though. It involves a small dose of radiation, it does not detect the soft, non-calcified plaque that causes many events in younger people, and a score of zero does not guarantee low risk in every situation. It is a tie-breaker for borderline cases, not a routine test for everyone, and it is best interpreted alongside the rest of the risk picture.

Primary prevention on the strength of a number alone

And then there is the group where the statin was started because a cholesterol result looked high, in an otherwise low-risk person, without a risk assessment ever being done. This group exists. When one of them presents with disabling muscle aches, the honest answer may be that the medication is doing very little for them and the conversation should be about whether it is needed at all.

Before we work out which statin you can tolerate, we should agree on what the statin is for. Sometimes that answer alone settles the question.

What the Evidence Says About Statin Muscle Symptoms

This is where the picture gets genuinely interesting, and where I think the public conversation has become unhelpfully polarised.

In randomised trials, where neither the patient nor the doctor knows who is receiving the statin, the rate of muscle symptoms is only slightly higher in the statin group than the placebo group. In everyday practice, reported rates are far higher, somewhere between 10% and 25% depending on the study.

Two trials have looked at this directly. In the SAMSON study, participants who had previously stopped statins because of side effects took months of statin tablets, months of placebo tablets, and months of no tablets at all, without knowing which was which. Symptom scores were almost identical in the statin months and the placebo months, and much lower in the months with no tablet. The StatinWISE trial, using a similar design, reached a comparable conclusion.

It would be easy to read that as proof the symptoms are imaginary. That is the wrong lesson, and it is the reading that makes patients feel disbelieved.

What those trials actually show is that the act of taking a daily tablet, combined with the expectation of a side effect, produces real physical symptoms. This is the nocebo effect, and it is a genuine physiological phenomenon, not a character flaw. The pain is real. Its origin is more complicated than the drug molecule alone.

They also do not exclude the existence of a smaller group with true statin-associated muscle injury. That group exists, is a minority, and is identifiable. It is also worth knowing that many people who stop a statin because of side effects turn out to tolerate one when it is reintroduced carefully, often at a lower dose or as a different agent, though this is something to explore with a doctor rather than attempt alone.

Telling the Difference in the Clinic

There is no single test that settles it, but the pattern of symptoms carries a lot of information.

Feature More typical of statin-related myalgia Less typical, consider other causes
Distribution Symmetrical, large muscle groups, thighs, calves, shoulders One limb, one joint, or a small localised area
Timing after starting Within four to six weeks of starting or a dose increase Years into stable therapy with no dose change
Character Aching, heaviness, weakness, cramping Sharp, burning, tingling, or clearly joint-centred
Response to stopping Improves within two to four weeks No change after stopping
Creatine kinase Normal or mildly raised in most cases Markedly raised suggests true muscle injury and needs prompt review

Other causes deserve a proper look before the statin takes the blame. An underactive thyroid, vitamin D deficiency, polymyalgia rheumatica, undiagnosed inflammatory arthritis, and simple deconditioning all produce muscle symptoms. So does a recent increase in physical activity, which frequently coincides with starting a statin because both often follow the same health scare.

One question comes up in almost every one of these conversations, so it is worth addressing directly. Statins lower the body’s levels of coenzyme Q10, and because CoQ10 is involved in how muscles produce energy, the theory that topping it up might ease statin muscle aches is a reasonable one. The trouble is that trials testing this have been small and their results inconsistent, so the evidence does not clearly support it. It is not something to take instead of talking the symptoms through with your doctor, but it is a fair thing to raise. Our article on CoQ10 and ubiquinol looks at what the research does and does not show.

Drug interactions matter too. Some antibiotics, antifungals, certain calcium channel blockers, and grapefruit juice raise blood levels of particular statins. A medication review sometimes solves the problem without changing the statin at all.

The Options When Symptoms Are Real

Assuming the indication is sound and other causes have been excluded, there is far more room to manoeuvre than most people realise. Very few patients truly cannot tolerate any lipid-lowering therapy. None of the points below is something to start or change on your own. They are the questions worth putting on the table when you sit down with your doctor, so the conversation covers the full range of what is possible rather than jumping straight to stopping.

Ask about the dose

Most of the LDL reduction from a statin comes at the lower end of the dose range, so it is worth asking whether a smaller dose might ease symptoms while keeping much of the benefit.

Ask about a different statin

Statins differ in how the body processes them, and someone who reacts to one often does well on another. Occasionally even trying a different brand of the same statin is worth raising.

Ask about the frequency

Some cardiologists discuss non-daily schedules, such as alternate days, particularly with longer-acting statins. It is a conversation to have with a doctor, never a change to make alone.

Ask about a partner medication

Pairing a lower statin dose with a second medication such as ezetimibe can reach a similar result to a high dose alone, which is worth asking about.

Ask about non-statin options

For genuine intolerance in higher-risk patients, PCSK9 inhibitors and bempedoic acid work by different mechanisms, the latter designed to bypass muscle, and are worth discussing.

Ask why it was started

Before adjusting anything, it is fair to ask what your actual cardiovascular risk is and what the statin is protecting against, since that shapes every other decision.

Why non-daily dosing is worth understanding

The idea of taking a statin three times a week strikes many people as either a compromise or a fudge. It is neither, and the reasoning is worth explaining.

Some statins remain active in the body well beyond 24 hours, so the cholesterol-lowering effect does not disappear on the off days. More importantly, the benefit of these medications is not confined to the LDL number. Statins reduce inflammation within the artery wall, thicken the fibrous cap over existing plaque, and make that plaque less likely to rupture. Plaque rupture is the event that causes most heart attacks. Much of that stabilising effect is achieved at modest, sustained exposure.

This is not a guideline recommendation and it should never be self-initiated. It is a strategy some cardiologists, including me, discuss with individual patients when the alternative is no treatment at all. Some treatment, taken reliably, beats optimal treatment abandoned after three weeks.

A newer option for genuine intolerance

For people who truly cannot tolerate statins and remain at high risk, the options have widened. Alongside the injectable PCSK9 inhibitors, a newer oral tablet called bempedoic acid has become part of the conversation. It lowers cholesterol through a different pathway to statins, and because it is only activated in the liver rather than in muscle tissue, it is far less likely to cause the muscle aches that statins can. In 2025 the European cholesterol guidelines strengthened their recommendation for it in statin-intolerant patients on the back of a large trial showing it reduced cardiovascular events.

It is not a perfect substitute. It can raise uric acid levels and trigger gout in people prone to it, and in Australia its cost and subsidy situation is still settling, so it is worth asking your doctor about availability as well as suitability. But for someone who has genuinely exhausted the statin options, it is a meaningful addition rather than a last resort, and a reason not to conclude too quickly that nothing can be done.

Working Through It With Your Doctor

The most useful thing you can bring to that appointment is detail. When the symptoms started in relation to starting the tablet. Which muscles. Whether both sides are affected equally. Whether anything else changed at the same time, including exercise, other medications, or an illness.

From there, doctors often work through it in a structured way. That might involve a supervised period off the statin to see whether symptoms genuinely resolve, blood tests to check for other contributors, then a carefully planned reintroduction at a lower dose or with a different agent. A temporary, planned break is a diagnostic step rather than a decision to stop, which is why it is done with your doctor rather than on your own.

It is also reasonable to ask directly what your cardiovascular risk actually is, and what this medication is expected to do about it. If that question has never been answered properly, answering it may be the single most valuable part of the consultation. Our overview of cardiovascular risk factors is a reasonable place to start before you go.

Heart Matters Resource

When in Doubt, Get Checked Out

Severe muscle pain with dark urine, or weakness that makes it hard to rise from a chair, needs same-day medical assessment rather than a wait-and-see approach.

Read: When in Doubt, Get Checked Out →

Conclusion

Muscle symptoms on a statin are not a reason to be dismissed, and they are not a reason to walk away from cholesterol treatment altogether. They are a reason for a proper conversation about why the medication was started, what it is protecting against, and which of the many available adjustments fits the person in front of you.

The patients who do best are the ones who raise the problem early rather than quietly stopping the tablet and mentioning it a year later. If a statin is making you ache, say so, and ask what the alternatives are. There are usually more of them than you have been told.

Nothing here is a recommendation about your own treatment. It is a map of what the conversation can cover, so that when you sit down with your GP or cardiologist you can talk through your particular risk factors and circumstances. That discussion, grounded in your situation rather than a general article, is where the right decision for you is made.

References

  • Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. New England Journal of Medicine 2020;383:2182-2184
  • Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials (StatinWISE). BMJ 2021;372:n135
  • Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale randomised double-blind trials. Lancet 2022;400:832-845
  • Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:e38-e81
  • Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance (GAUSS-3). JAMA 2016;315:1580-1590

Related Reading

Top 5 Kitchen Gadgets for a Healthier Heart

KITCHEN GADGETS
Key Points
  • The kitchen tools you use shape the food you produce. A small number of inexpensive gadgets make heart-healthy cooking consistently easier, faster, and more precise.
  • A kitchen scale is the single most impactful nutritional tool available. It removes the guesswork from portion sizes and makes the difference between thinking you are eating well and knowing you are.
  • An oil spray bottle gives precise control over fat intake, one of the most meaningful variables in everyday cardiovascular nutrition.
  • An air fryer produces the texture of fried food with a fraction of the oil, making a genuinely enjoyable cooking method compatible with a heart-healthy diet.
  • A food processor and a quality non-stick pan complete the toolkit, reducing the friction between good nutritional intentions and what actually ends up on the plate.

Good nutrition does not require extraordinary willpower or complicated meal plans. It requires removing the friction between good intentions and good execution, and the right kitchen tools do exactly that.

None of the five items below are expensive. None require culinary skill to use. But each one makes a specific and meaningful difference to the ease, consistency, and nutritional quality of everyday cooking. These are the tools that earn their place on the bench, not through novelty but through regular, practical use.

1. Kitchen Scales

The kitchen scale is the most impactful nutritional tool available for the least investment. It costs very little, takes up almost no space, and removes the single biggest source of nutritional inaccuracy in home cooking: portion estimation.

Most people significantly underestimate portion sizes when using visual judgment alone. A handful of almonds varies by a factor of three depending on hand size and generosity. A drizzle of olive oil can be anywhere from 5ml to 40ml. A portion of pasta is almost always double what a nutritional target would suggest. None of this matters if you are eating well and maintaining a healthy weight effortlessly. But for most people trying to manage their nutrition with any precision, visual estimation is not reliable enough.

Weighing food does not need to be obsessive or permanent. A few weeks of accurate weighing builds the visual calibration that makes estimation more accurate going forward. For ingredients where precision genuinely matters, like olive oil, the scale is the most honest tool available.

We have a dedicated article on kitchen scales and portion awareness on Heart Matters that explores this in more detail.

2. Oil Spray Bottle

Of all the tools on this list, the oil spray bottle may be the one with the most direct cardiovascular impact per dollar spent. It is a refillable spray bottle filled with your oil of choice (extra virgin olive oil is the obvious recommendation) that delivers a fine, even mist rather than a pour.

The difference between a spray and a pour is significant. A two-second spray delivers approximately 1 to 2ml of oil, around 9 to 18 calories. A casual pour from a bottle delivers anywhere from 15 to 40ml without most people registering the difference. Over a week of daily cooking, that gap accumulates into a meaningful calorie and fat differential.

The spray bottle also coats pans more evenly than a pour, which means food is less likely to stick, reducing the instinct to add more oil mid-cooking. For roasting vegetables, a light spray produces excellent results with minimal fat. For the high-protein breakfast frittata, it gives precise control over the fat used in cooking while preserving all the benefits of olive oil.

Fill it with extra virgin olive oil, consistent with the Mediterranean dietary pattern, and use it as the default cooking fat across every meal.

3. Air Fryer

The air fryer deserves its place on this list not as a novelty appliance but as a genuinely useful cardiovascular cooking tool. It circulates hot air at high speed around food, producing a crisp exterior texture that is indistinguishable from shallow or deep frying, with a fraction of the oil.

The cardiovascular relevance is straightforward. Deep frying adds significant quantities of oil to food that may have started as nutritionally excellent, and depending on the oil used, significant quantities of saturated or trans fat with it. An air fryer produces the same texture without the oil load, making a cooking method that many people find genuinely enjoyable compatible with a heart-healthy diet.

Chicken breast, fish, vegetables, sweet potato: all produce excellent results in an air fryer with a light oil spray and appropriate seasoning. Cooking times are typically shorter than oven roasting, and the cleanup is straightforward. Our air fryer salmon with pumpkin chips and broccoli is a complete demonstration of what this appliance can do for a heart-healthy plate. For anyone who has avoided fried textures as part of managing their diet, the air fryer is the tool that removes that sacrifice.

4. Food Processor

The food processor is the tool that makes hidden nutrition practical. Blitzing broccoli into fine crumbs that disappear into a frittata, processing cauliflower into rice, blending vegetables into sauces: these techniques dramatically expand the vegetable content of everyday meals without requiring any change to eating preferences.

The blitzed broccoli technique from our high-protein breakfast frittata is the clearest demonstration. In 10 seconds, a food processor turns a broccoli floret into fine green crumbs that integrate seamlessly into egg dishes, pasta sauces, meat patties, and soups. The sulforaphane, vitamin C, folate, and fibre are all present. The broccoli is not detectable.

A food processor also makes batch preparation faster: grating large quantities of vegetables, processing cooked chicken for salads, or blending dressings and marinades in seconds. For anyone who finds vegetable preparation tedious, it is the tool that removes that specific friction from the cooking process.

5. A Quality Non-Stick Pan

The quality of a non-stick pan directly affects how much oil is needed in everyday cooking. A worn, damaged non-stick surface requires significantly more fat to prevent food from sticking, creating a gradual, unnoticed increase in fat intake that accumulates over weeks and months.

A good non-stick pan, replaced when the surface begins to degrade, allows eggs, fish, and vegetables to cook with minimal oil and release cleanly. Combined with an oil spray bottle, it is the equipment combination that makes genuinely low-fat cooking practical without sacrificing the cooking experience.

Ceramic non-stick pans have become a popular alternative to traditional coated pans. They perform well at moderate temperatures and are a clean, practical option for everyday use. Either style, properly maintained and replaced when worn, does the job. A quality non-stick pan in the $30 to $80 range is all that is needed.

The kitchen tools you invest in shape the food you produce far more than most people realise. A scale, a spray bottle, and a good pan change every meal for years.

The Complete Toolkit at a Glance

Tool Primary cardiovascular benefit Approximate cost
Kitchen scale Accurate portion sizes that remove nutritional guesswork entirely $15–$40
Oil spray bottle Precise fat control, the most impactful fat management tool available $10–$25
Air fryer Crisp texture with minimal oil, making enjoyable cooking compatible with heart health $80–$200
Food processor Hidden vegetable nutrition, making high-fibre batch preparation practical $50–$150
Quality non-stick pan Minimal oil cooking, the foundation of everyday low-fat meal preparation $30–$80

Where to Start

  • Buy the kitchen scale first. It costs the least and has the most immediate impact on nutritional accuracy.
  • Add the oil spray bottle next. Fill it with extra virgin olive oil and use it for every meal that requires cooking fat.
  • Replace your non-stick pan if the surface is worn. This is the change that makes the scale and spray bottle work together most effectively.
  • Add the food processor when you are ready to expand your vegetable repertoire and make batch preparation practical.
  • Consider the air fryer if fried textures are a regular part of your diet that you have been trying to reduce. It removes the compromise entirely.

Heart Matters Resource

Download our Heart Health Risk Factor Checklist, a practical tool covering 12 cardiovascular risk categories to bring to your next appointment.

Download the Resource →

Conclusion

Good cardiovascular nutrition does not require an expensive kitchen, complicated equipment, or culinary training. It requires removing the friction between good intentions and consistent execution, and these five tools do exactly that, reliably, every day.

A kitchen scale, an oil spray bottle, an air fryer, a food processor, and a quality non-stick pan represent a total investment of well under $500, and they change the nutritional quality of every meal cooked at home for years. Start with the scale and the spray bottle, add the others as they become relevant to how you cook, and the cumulative effect on your daily nutrition will be significant.

Related Reading

Aortic Dissection: The Chest Pain That Cannot Wait

aortic dissection
Key Points

  • An aortic dissection is a tear in the wall of the aorta, the body’s main artery. It is a medical emergency, and every minute counts.
  • The warning sign is sudden, severe chest or back pain, often described as ripping or tearing, and often the worst pain a person has ever felt. It arrives at full intensity within seconds rather than building gradually.
  • Long term high blood pressure is the single biggest risk factor. Most people who have a dissection have had raised blood pressure for years.
  • Inherited conditions such as Marfan syndrome, and a family history of aortic aneurysm or unexplained sudden death, substantially increase risk and are a reason to ask about screening.
  • Dissection is easily mistaken for other conditions, and a normal ECG or normal blood test does not rule it out. If the pain fits the pattern, call 000.

Most cardiac emergencies announce themselves gradually. A heaviness in the chest that builds over minutes. A tightness that comes on with exertion and eases with rest. An aortic dissection does not behave this way. It arrives at full force, without warning, in people who felt perfectly well moments earlier.

It is the emergency that gives no notice. A person is well in the morning, well over lunch, and in cardiac arrest by the evening. That pattern is not a rare exception to how dissection behaves. It is characteristic of it.

Understanding what an aortic dissection is, who is at risk, and above all what it feels like, is the difference between a call to emergency services and a fatal delay.

What Is an Aortic Dissection?

The aorta is the largest blood vessel in the body. It leaves the heart, arches over the top of it, and travels down through the chest and abdomen, carrying every drop of blood the heart pumps out to the rest of the body. It is roughly the width of a garden hose, and it withstands enormous pressure with every heartbeat.

The wall of the aorta is made of three layers, bonded together. A dissection begins when the innermost layer develops a tear. Blood, travelling at high pressure, is forced into that tear and begins to push the layers apart, carving a false channel along the length of the vessel.

Once that channel opens, several things can go badly wrong at once. The false channel can compress the true one, starving organs of blood. It can extend into the branches that supply the brain, kidneys, or the heart muscle itself. It can rupture entirely. And if the tear is close to the heart, blood can leak into the sac that surrounds it, squeezing the heart until it can no longer pump.

The Two Types, and Why the Difference Matters

Doctors classify dissections by where the tear sits. This is not academic. The two types are treated in fundamentally different ways.

Type A dissections involve the ascending aorta, the section closest to the heart. These are surgical emergencies. The tear can extend backwards into the sac around the heart or shear off the arteries feeding the heart muscle, and either can cause sudden cardiac arrest. Type A dissections are taken directly to theatre.

Type B dissections are confined to the descending aorta, further down the chest. These are often managed initially with aggressive blood pressure control in intensive care, with a stent placed inside the vessel in selected cases. Surgery is not always the first step.

Type A

The tear involves the section of aorta nearest the heart. This is the more dangerous form and is treated as an immediate surgical emergency.

Type B

The tear is confined to the descending aorta, further from the heart. Often managed first with intensive blood pressure control, and sometimes a stent.

Why Time Matters

For an untreated Type A dissection, the risk of death rises with every hour that passes after the tear. This is why it is never something to wait out.

What It Actually Feels Like

This is the section worth remembering, because recognising the pain is what gets people to hospital in time.

The classic symptom is sudden, severe pain in the chest or back. Patients describe it as ripping, tearing, or being stabbed. It is frequently described as the worst pain of their life. Two features set it apart from most other chest pain.

First, the onset. It does not build. It is maximal within seconds. People can often tell you exactly what they were doing at the moment it began.

Second, it can move. As the tear extends along the vessel, the pain can travel, migrating from the front of the chest through to between the shoulder blades, or down into the abdomen.

Dissection can also present in ways that look like something else entirely. Stroke-like symptoms if the tear reaches the arteries to the brain. Abdominal pain. Fainting. A leg that suddenly turns cold and pale. In the most severe cases, the first sign is collapse. This was the pattern in the widely reported death of United States Senator Lindsey Graham in July 2026, whose office cited preliminary findings of an aortic dissection due to arteriosclerotic cardiovascular disease. He was 71, had recently returned from an overseas trip, and had shown no sign of being unwell.

Chest pain that arrives at full intensity in an instant, and is described as tearing or ripping, is not a wait and see symptom. It is a call an ambulance symptom.

Why Blood Pressure Sits at the Centre of This

The most important thing to understand about dissection is that in the majority of cases, it is the endpoint of a process that has been building quietly for years.

Every heartbeat sends a pulse of pressure through the aortic wall. Over decades, persistently high blood pressure stresses that wall, stiffening it and degrading the elastic tissue that holds the layers together. Add the plaque and inflammation of atherosclerosis, the same disease process that drives most heart attacks and strokes, and the wall becomes progressively less able to tolerate the pressure it is subjected to.

Chronic hypertension is the single biggest modifiable risk factor for aortic dissection, and it is present in the large majority of cases. This is the uncomfortable but hopeful part of the story. A condition that kills within minutes is driven, more than anything else, by a number that can be measured at home in 60 seconds and treated effectively.

The other well-recognised contributors are:

  • Age and sex. Dissection most commonly affects men in their 60s and 70s, though it can occur far younger, particularly where there is an inherited cause.
  • Smoking. Tobacco accelerates the arterial damage that weakens the aortic wall.
  • An existing aortic aneurysm. A vessel that has already enlarged is a vessel more likely to tear.
  • Stimulant drug use. Cocaine and amphetamines cause abrupt, extreme blood pressure surges.
  • Pregnancy. Uncommon, but a recognised period of increased risk in women with underlying aortic disease.

The Genetic Side, and When Family History Matters

Not every dissection is a story about decades of blood pressure. A meaningful minority occur in younger people whose aortas were structurally vulnerable from birth.

Inherited connective tissue conditions

Marfan syndrome is the best known. It affects the connective tissue that gives the aortic wall its strength, and people with Marfan syndrome can experience dissection in their 30s or 40s. Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome carry similar risk. These conditions often, though not always, come with recognisable physical features such as tall stature, long limbs and fingers, and problems with the lens of the eye.

Bicuspid aortic valve

Some people are born with an aortic valve that has two leaflets instead of the usual three. This is one of the most common congenital heart differences, and it is associated with weakness in the wall of the ascending aorta, independent of any valve problem. It is also relevant to aortic stenosis later in life.

Familial aortic disease with no syndrome attached

This is the group most often missed. Some families carry a tendency to aortic aneurysm and dissection without any of the classical syndromes and without any outward clues. The only signal is the family history itself.

If a parent, sibling, or child has had an aortic aneurysm, an aortic dissection, or an unexplained sudden death, that is worth raising with your doctor. Imaging can measure the size of the aorta long before it is in danger, and an aorta that is enlarging can be monitored, treated with blood pressure medication, and repaired electively. Elective repair is a very different proposition to emergency surgery on a tearing vessel.

Why It Is So Easily Missed

Aortic dissection is one of medicine’s great imitators, and this is worth understanding because it affects what you should do.

The standard tests used to assess chest pain, an ECG and a blood test for cardiac enzymes, can be entirely normal while the aorta is tearing. A chest X-ray is often unremarkable. The diagnosis usually rests on a CT scan of the aorta, and that scan only gets ordered if someone thinks to order it.

This has two practical implications. If you experience sudden tearing chest or back pain, say so in exactly those words to the paramedics and to the doctor in the emergency department. The description matters. And if you have a family history of aortic disease, say that too, unprompted. It changes how the pain in front of the doctor is interpreted.

It is entirely reasonable, in that situation, to ask directly whether an aortic dissection has been considered. Good clinicians will not be offended by the question.

What You Can Actually Do

The measures that protect the aorta are not exotic. They are the same measures that protect the rest of the cardiovascular system, applied consistently over years.

Know your blood pressure and treat it. If you have been prescribed medication for it, take it. This matters more than any other single action, and there is a great deal you can do alongside medication to help bring the numbers down.

Do not smoke. Treat raised cholesterol. Stay physically active. Understand your overall cardiovascular risk profile rather than any single number in isolation.

And know the alarm symptom. Sudden, severe, tearing chest or back pain, arriving at full intensity, in a person who was well moments before, is an emergency until proven otherwise. In Australia, call 000. Do not drive yourself. Do not wait to see whether it settles.

Conclusion

An aortic dissection is one of the few conditions in cardiovascular medicine where outcome is measured in minutes rather than hours or days. It is also, for most people, the final chapter of a much longer and much quieter story, one written by years of untreated blood pressure and arterial damage. That is the part that is within reach.

Take the blood pressure reading. Ask about the family history. And if the pain ever comes, sudden and tearing and unlike anything before it, do not talk yourself out of the phone call.

Related Reading

Demystifying Heart Failure: HFrEF, HFpEF and HFimpEF Explained

heartmatters.com 2026 04 01T171429.222
Key Points

  • Heart failure does not mean the heart has stopped or is about to. It means the heart is not pumping or filling as efficiently as it should, and in many cases this can be treated and even improved.
  • The confusing letters (HFrEF, HFpEF, and the newer HFimpEF) all describe one thing: the ejection fraction, or how much blood the main pumping chamber squeezes out with each beat.
  • Cardiologists separate these types because the underlying problem and the best treatment differ. The same label points the whole team toward the right medicines.
  • HFimpEF (improved ejection fraction) is the hopeful category. It describes people whose heart function has recovered, and the key lesson is that the medicines usually need to continue.
  • A new international consensus, the Second Universal Definition of Heart Failure published in June 2026, reframes heart failure as a condition that can change over time, with more focus on catching it early.

You have been told you have heart failure, and within the same conversation you have heard HFrEF, HFpEF, and perhaps HFimpEF. It sounds like alphabet soup, and it arrives at exactly the moment you are least equipped to decode it. The good news is that these terms are far less frightening once you understand what they are actually measuring, and why your cardiologist cares about the difference.

This article breaks the language down into plain English: what heart failure really means, what those letters stand for, why the distinction matters for your treatment, and what a major new international definition, published in June 2026, changes for patients.

Start With What Heart Failure Actually Means

The name is one of the cruellest in medicine. “Failure” suggests something has stopped, or is about to. That is not what it means. Heart failure is a clinical syndrome in which the heart cannot pump or fill with blood as efficiently as the body needs, usually producing symptoms such as breathlessness, fatigue, and swelling in the legs and ankles.

Crucially, it is not a single disease and it is not a death sentence. It is a description of how the heart is performing, and modern treatment can stabilise it, ease symptoms, and in a meaningful number of people improve the heart’s function substantially. To understand the categories, you first need to understand one number.

The Number Behind the Letters: Ejection Fraction

Every time the heart’s main pumping chamber, the left ventricle, contracts, it squeezes a percentage of the blood inside it out to the body. That percentage is the ejection fraction, usually shortened to EF. It is measured most often on an echocardiogram, the heart ultrasound.

A normal left ventricle does not empty completely. A healthy EF sits somewhere around 55% to 70%. So an EF of 60% is normal, not a sign that 40% is being left behind in a worrying way. This is the single most misread number in a cardiology report, so it is worth pausing on: a lower EF means the pump is weaker, but the EF is only one part of the picture, and it is not the whole story of how you will feel or fare.

The Three Main Types, Explained

Heart failure is grouped by ejection fraction because that number, more than almost anything else, tells the cardiologist what kind of problem they are dealing with and which treatments are likely to help. Here are the categories you are most likely to hear.

HFrEF: heart failure with reduced ejection fraction

This is the “weak pump” type. The EF is reduced, conventionally 40% or below, meaning the left ventricle is not contracting forcefully enough. The heart muscle has usually been damaged or weakened, and the squeeze is impaired. HFrEF is the type with the largest body of evidence behind its treatment, and, importantly, the type where the right combination of medicines can make the biggest difference.

HFpEF: heart failure with preserved ejection fraction

Here the EF is preserved, conventionally 50% or above, so the pump looks normal on paper. The problem is not the squeeze but the relaxation and filling. A stiff left ventricle cannot relax properly between beats, so it fills poorly and pressure backs up, producing the same symptoms of breathlessness and swelling. HFpEF is more common in older adults, in women, and in people with long-standing high blood pressure, diabetes, or obesity. For years it was the harder type to treat, though that has changed recently.

HFimpEF: heart failure with improved ejection fraction

This is the newest and most hopeful category. It describes someone who started with a reduced EF (40% or below) and, with treatment, has seen it recover to above 40%. Their heart has improved. The vital message attached to this label, and the reason cardiologists coined it rather than simply calling the person “better,” is that the improvement is usually because of the medicines, not instead of them. Stopping treatment because the numbers look good is one of the most common ways people relapse.

You may also hear HFmrEF, heart failure with mildly reduced ejection fraction, describing the middle band where EF sits between 41% and 49%. Think of it as the territory between the reduced and preserved categories, treated with a foot in both camps.

HFrEF: reduced

The pump is weak. Ejection fraction 40% or below. The muscle is not squeezing hard enough. Strong evidence exists for treatment that helps the heart recover.

HFpEF: preserved

The pump looks normal (EF 50% or above) but the ventricle is stiff and fills poorly. More common with age, in women, and with high blood pressure or diabetes.

HFimpEF: improved

Started reduced, now recovered above 40%. The good-news category, with one rule: the medicines that produced the recovery usually need to continue.

Why Cardiologists Bother Splitting Hairs

It is a fair question. If the symptoms are similar, why label the types at all? The answer is that the underlying mechanics are genuinely different, and so is the treatment that works. A medicine proven to save lives in a weak, reduced-EF heart may do little for a stiff, preserved-EF heart, and vice versa. The category is not bureaucratic tidiness. It is the shorthand that points your whole care team toward the treatments most likely to help you, and away from ones that will not.

Getting the category right also shapes what your cardiologist watches over time, from your BNP blood test to repeat scans that track whether your EF is holding steady, worsening, or improving.

The table below sets the three types side by side. It is a map, not a diagnosis, and your own cardiologist remains the person who reads it onto your particular heart.

Feature HFrEF (reduced) HFpEF (preserved) HFimpEF (improved)
Ejection fraction 40% or below 50% or above Was 40% or below, now above 40%
Core problem A weak squeeze A stiff chamber that fills poorly A previously weak heart that has recovered
More common in People with prior muscle damage or a weakened heart Older adults, women, and people with high blood pressure or diabetes People treated early and effectively for HFrEF
Treatment focus The four pillars of medicine, built up together Treating the drivers, plus SGLT2 inhibitors Continuing the medicines that produced the recovery
Outlook message Strong evidence that treatment helps Improving fast as new evidence arrives The hopeful category, if treatment continues

The label is not there to frighten you. It is there to make sure the right medicine reaches the right heart.

What Causes Each Type

The causes overlap, but they cluster differently across the categories, and identifying the cause is often as important as measuring the EF.

Reduced-EF heart failure most often follows damage to the heart muscle: a previous heart attack that has left a weakened area, longstanding uncontrolled blood pressure, disease of the heart muscle itself (the cardiomyopathies), heart rhythm problems such as atrial fibrillation, valve disease, or, in some people, alcohol and certain toxins.

Preserved-EF heart failure tends to grow out of years of a heart working against stiffening and pressure: chronic high blood pressure, diabetes, obesity, obstructive sleep apnoea, and ageing itself. Less commonly, an infiltrative condition such as cardiac amyloidosis stiffens the muscle, which matters because some of these causes now have specific treatments.

Improved-EF heart failure, by definition, starts as the reduced type and gets better, usually because the cause was treatable and the treatment worked. That is precisely why the medicines are rarely a temporary measure.

How Each Type Is Treated

This is where the categories earn their keep. The following is a general map, not a prescription. The right combination, and every dose, is individual, and only your own cardiologist can advise what is right for you.

For reduced-EF heart failure, the modern approach uses four classes of medicine together, often called the four pillars or quadruple therapy. In broad terms these are a medicine that relaxes and protects the blood vessels and heart (an ACE inhibitor, an ARB, or the combination agent Entresto), a beta-blocker, a mineralocorticoid receptor antagonist such as spironolactone, and an SGLT2 inhibitor. Used together and built up carefully, this combination has transformed outcomes over the past decade.

For preserved-EF heart failure, the picture has brightened considerably. SGLT2 inhibitors now have good evidence here too, which was not the case a few years ago. Beyond that, the priority is treating the drivers: controlling blood pressure and diabetes, managing weight, addressing sleep apnoea, and using diuretics to clear the fluid that causes congestion and breathlessness. Treating the specific cause, where there is one, matters more in this group than in any other.

For improved-EF heart failure, the treatment is, in most cases, to keep going. Trials have shown that stopping the medicines once the heart has recovered often allows the weakness to return. The recovery is best understood as the treatment succeeding, not as the illness disappearing, and the safest path is to maintain the therapy under your cardiologist’s guidance. Never stop a heart failure medicine without speaking to them first.

What the New 2026 Definition Changes

In June 2026, the world’s leading cardiovascular bodies, including the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the World Heart Federation, published the Second Universal Definition of Heart Failure, simultaneously in the journals JACC, Circulation, the European Heart Journal, and Global Heart. The American Heart Association has also released a plain-language summary for patients. It updates the first such definition from 2021, and although the document is written for clinicians, several of its changes matter to patients.

64 million
adults worldwide are estimated to live with heart failure, a number driven up by ageing populations and rising rates of high blood pressure, diabetes, and obesity.
American Heart Association, June 2026

First, it moves away from rigid cut-off numbers for ejection fraction and acknowledges that a normal EF differs by sex, age, and ethnicity, while keeping the familiar reduced, preserved, and improved categories as practical guides. Second, it puts far greater emphasis on catching heart failure early, before symptoms appear, so that prevention and treatment can start sooner. Third, and perhaps most reassuringly, it formally describes heart failure as a dynamic condition that can improve, go into remission, or progress, rather than a fixed, one-way diagnosis. The document is intended to be the foundation for the next major heart failure guideline, expected in 2027.

For a patient, the takeaway is encouraging: the field increasingly sees heart failure not as a static verdict but as a condition to be caught early, categorised accurately, and, in many people, improved.

Questions Worth Asking at Your Next Appointment

  • Which type of heart failure do I have, and what does that mean for my treatment?
  • What is my ejection fraction, and has it changed since my last echocardiogram?
  • Am I on the right combination of medicines for my specific type?
  • Are there conditions contributing to my heart failure, such as blood pressure, diabetes, or weight, that we should be managing more closely?
  • What symptoms should prompt me to contact the team between appointments?

Heart Matters Resource

When in Doubt, Get Checked Out

New breathlessness, unusual tiredness, or swelling in the legs are worth having assessed early. Heart failure is far more treatable when it is picked up sooner rather than later.

Read: When in Doubt, Get Checked Out →

Conclusion

The terminology around heart failure sounds far more alarming than the reality for most people. HFrEF, HFpEF, and HFimpEF are simply three ways of describing how well the heart’s main chamber is pumping and filling, and each points toward a different and increasingly effective set of treatments. The letters are a tool for getting you the right care, not a measure of how worried you should be.

If you have been given one of these labels, the most useful thing you can do is understand which type you have, take the medicines as prescribed even if you feel well, and keep the conversation with your cardiologist going. Heart failure is more treatable today than at any point in medical history, and, as the newest category reminds us, it can genuinely improve.

Related Reading

CoQ10 and Your Heart: What the Evidence Actually Shows

heartmatters.com 51

CoQ10 is a widely used supplement, especially among people on statins, but the evidence is more mixed than the marketing suggests. Here is what it can and can’t do, who might benefit, and the interactions that matter if you are on a blood thinner.

Vascepa and Vazkepa: What This Prescription Omega-3 Actually Does

Vascepa Vazkepa
Key Points

  • Vascepa and Vazkepa are two brand names for the same prescription medication, icosapent ethyl, a highly purified form of the omega-3 fatty acid EPA. The medication is sold as Vascepa in the United States and as Vazkepa across Europe, the United Kingdom, Australia and other markets. Neither is the same as an over-the-counter fish oil supplement.
  • It is prescribed as an add-on for people already taking a statin who have raised triglycerides and are at high risk of a heart attack or stroke. It is not a replacement for a statin.
  • The REDUCE-IT trial found it reduced the risk of serious cardiovascular events by 25% in this group, a result that changed guidelines in several countries.
  • The dose is two 998 mg capsules twice daily, four capsules a day in total, always taken with a meal. Food is essential for proper absorption.
  • The two side effects to know about are a small increased risk of atrial fibrillation and an increased tendency to bleed. Tell your doctor and pharmacist about every other medication you take. Never stop without speaking to your cardiologist first.

For many years, cardiologists recommended fish oil capsules to patients with high triglycerides, and the evidence was modest at best. Then in 2018 a major clinical trial changed the conversation.

The REDUCE-IT trial reported that a specific prescription omega-3 medication reduced the risk of heart attack, stroke, and cardiovascular death in high-risk patients already on statin therapy. The results prompted cardiologists to rethink how they managed this group. This article explains what the medication is, who it is for, how it works, and what to expect if you have been prescribed it.

What Are Vascepa and Vazkepa?

Vascepa and Vazkepa are two brand names for the same medication, icosapent ethyl, a highly purified, prescription-strength form of EPA, one of the omega-3 fatty acids found in oily fish. It was first approved in the United States, where the REDUCE-IT trial was run, and is sold there as Vascepa. In Europe, the United Kingdom, Australia and a number of other markets it is sold as Vazkepa. The active ingredient and the dose are identical, so everything in this article applies equally to both.

What makes this medication different from a standard fish oil supplement is that it contains only EPA, with no DHA, and it is manufactured to a far higher standard of purity. That distinction matters clinically, and we will come back to it in the comparison section below.

How Does It Work?

The medication lowers blood triglycerides, a type of fat that circulates in the bloodstream. At the full prescribed dose it typically reduces triglycerides by around 20 to 30%. The cardiovascular benefit seen in REDUCE-IT was larger than triglyceride lowering alone could explain, and researchers believe several additional mechanisms are involved.

Lowers triglycerides

Reduces this blood fat by about 20 to 30% at the full prescribed dose.

Reduces inflammation

EPA enters blood vessel walls, where it may cool the chronic inflammation that drives arterial plaque.

Stabilises plaque

May make existing fatty deposits more stable and less likely to rupture, the event that triggers most heart attacks.

Reduces platelet stickiness

Platelets are the cells that clump to form clots. Making them less sticky may reduce the risk of a dangerous blockage.

The precise contribution of each pathway is still being studied. You can read more about how inflammation drives heart disease in a separate article.

Who Is It Prescribed For?

This medication is not for everyone. It is mainly used to lower heart risk in people who are already taking a statin but still have raised triglycerides, and who are at high risk because they have already had heart trouble or have diabetes alongside other risk factors. In some countries it is also used to bring down very high triglyceride levels. It is taken alongside a statin, not instead of one.

The exact rules for who can be prescribed it differ from one country to another, and they change over time. So the only reliable answer to “is this right for me?” comes from your own doctor, who can weigh it against your personal situation. Always check with your cardiologist or GP before assuming it does or does not apply to you.

This is not a fish oil capsule from the supermarket. It is a purified, prescription medicine with trial evidence behind it, for a specific group of high-risk patients already on a statin.

Prof. Peter Barlis, Interventional Cardiologist

The REDUCE-IT Trial

The evidence behind this medication comes largely from one landmark clinical trial.

8,179
Patients across 11 countries
4.9
Years average follow-up
25%
Reduction in serious heart events vs placebo
2018
Published in the New England Journal of Medicine

All participants were on stable statin therapy with raised triglycerides. Roughly 70% had already had cardiovascular disease, while the rest had diabetes and additional risk factors. They were randomly assigned to receive either icosapent ethyl or a placebo, a dummy capsule with no active ingredient.

The result was a 25% reduction in serious heart events, a group that included heart attacks, strokes, cardiovascular deaths, and hospital admissions for severe chest pain. Put another way, several fewer people in every hundred had a serious heart event over about five years. In a population already at elevated risk, that is a meaningful difference.

25%
lower risk of serious cardiovascular events in high-risk patients on statin therapy, a result that prompted guideline updates in several countries.
REDUCE-IT trial, New England Journal of Medicine, 2018

How to Take It

The approved dose is two 998 mg capsules twice daily, four capsules a day in total, taken with meals. Food is not optional here. The medication is far better absorbed when taken with food, so the capsules should always be swallowed whole with or just after a meal, never crushed or chewed.

Morning
2 x 998 mg capsules
Take with your morning meal. Swallow whole. Do not crush or chew.
Evening
2 x 998 mg capsules
Take with your evening meal. Storing capsules in the fridge can reduce any fishy aftertaste.

This is a long-term medication whose benefits accumulate over time. If you miss a dose, take your next one as normal with your next meal, and do not double up. The dose and duration are individual, and only your cardiologist can advise what is right for you. Never stop taking it without speaking to your cardiologist first.

Side Effects to Know About

The medication is generally well tolerated, and most people take it without significant problems. Two effects deserve specific attention.

Atrial fibrillation

REDUCE-IT found a small increase in atrial fibrillation, the most common abnormal heart rhythm. The absolute increase was modest. Worth discussing with your cardiologist if you have a history of AF or palpitations.

Increased bleeding tendency

It reduces platelet stickiness, which can increase the tendency to bleed. In the trial, bleeding events were modestly more common than with placebo (around 12% versus 10%), and the risk was greater in people also taking blood-thinning medications such as aspirin, clopidogrel, or warfarin. Tell your doctor and pharmacist about every medication you take.

Other reported effects include constipation, swelling of the hands, feet, or legs, joint or muscle pain, gout, and a fishy aftertaste. Serious reactions are uncommon. Because this is a relatively new medicine, it remains under additional safety monitoring in many countries, and any side effects can be reported to your doctor or your national medicines regulator.

How It Differs From Standard Fish Oil

Many patients ask whether this is just an expensive fish oil capsule. It is not, and the difference is clinically important.

Vascepa / Vazkepa (prescription) Standard fish oil (over the counter)
Active ingredient EPA only, highly purified Mix of EPA and DHA, typically 30 to 40% omega-3
Manufacturing standard Pharmaceutical grade Supplement grade
Contains DHA No Yes
Effect on LDL cholesterol Neutral to slightly favourable DHA may raise LDL slightly
Cardiovascular trial evidence REDUCE-IT: 25% fewer serious heart events No comparable outcome data
Suitable for vegetarians No, fish-derived EPA and capsule shell Most are not, check labelling

The absence of DHA is deliberate. DHA may raise LDL cholesterol slightly, potentially offsetting some of the benefit, which may be part of why this medication performed differently from standard fish oil in trials. It is worth being clear about one practical point: because both the EPA and the capsule shell are fish-derived, the medication is not suitable for vegetarians, vegans, or people who avoid fish products for religious or cultural reasons, and there is currently no approved vegetarian alternative with the same evidence. If this applies to you, raise it with your cardiologist rather than simply stopping.

Cost and Availability

Because this is a prescription medication rather than a supplement, how much you pay depends heavily on where you live and how your healthcare system works. In some countries it is subsidised through a national scheme or covered by insurance for patients who meet specific criteria, which can reduce the cost substantially. In others it is paid for privately and can be expensive. Approval status and the exact eligibility rules also differ from country to country, and they change over time. The reliable approach is to ask your cardiologist or pharmacist about availability, eligibility, and cost where you live, rather than relying on a figure you read online.

Common Questions

Can I replace my statin with it? No. It works alongside a statin, not instead of one, and all the trial evidence comes from patients already on statin therapy.

Will it show up on a blood test? Yes. Your triglyceride level will fall, and your cardiologist will likely recheck your lipids a few months after starting to confirm it is working as expected.

How long until it works? The triglyceride-lowering effect appears within weeks, but the cardiovascular benefit builds over years of consistent use. This is a medicine for the long term, not a short course.

Heart Matters Resource

When in Doubt, Get Checked Out

If you have raised triglycerides and established heart risk, whether a medication like this fits your care is a conversation worth having. Your cardiologist can weigh it against the rest of your treatment plan.

Read: When in Doubt, Get Checked Out →

Conclusion

For a specific group of patients, those already on a statin with raised triglycerides and significant heart risk, the REDUCE-IT evidence shows that icosapent ethyl, whether dispensed as Vascepa or Vazkepa, can reduce the chance of a serious cardiovascular event. It is not a treatment for everyone, and it is not a substitute for the rest of your care.

If you have been prescribed it, take it consistently with meals, keep your pharmacist informed about all your other medications, and attend your regular blood test appointments. That is what gives this medication the best chance of working well for you.

And if you have read this wondering whether it might help you, the most useful next step is simply to ask. Whether this medication is suitable for you depends on your own health, your other medicines, and your level of risk, and only a doctor who knows your history can make that call. Always check with your cardiologist or GP before starting, stopping, or changing any treatment.

Related Reading